Atlas Arteria (M82) AI Stock Analysis
Atlas Arteria
(Frankfurt:M82)
No summary available
Atlas Arteria (M82) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 3.84B
- Dividend Yield
- 10.25%
- Average Volume (3M)
- 1,511
- Price to Earnings (P/E)
- 19.5
- Beta (1Y)
- 0.45
- Revenue Growth
- -0.55%
- EPS Growth
- 10.50%
- Country
- Germany
- Employees
- 50
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Industrial - Infrastructure Operations
Atlas Arteria Business Overview & Revenue Model
Company Description
Atlas Arteria Limited specializes in the acquisition, development, and management of toll road assets. Among its key holdings is a 13.4% equity stake in Toll Road Investors Partnership II (TRIP II), the concessionaire responsible for the 22-kilometer...
Atlas Arteria Earnings Call Summary
The call presented a mixed picture. Operationally the portfolio showed resilience — underlying NPAT rose 29%, constant-currency revenue and EBITDA were marginally positive, Dulles and Chicago traffic grew, APRR issued EUR 500m of bonds, and the company maintained its $0.40 distribution guidance while strengthening liquidity. Offsetting this were sizable one-off non-operating charges (put option accounting and settlement, takeover and change-of-control costs), adverse FX translating to a ~3.9% revenue and ~3.6% EBITDA decline in AUD terms, a TRIP bond downgrade, and governance/ownership uncertainty following IFM increasing its stake to ~67%. Overall the operational positives are meaningful but balanced by significant near-term headwinds and one-off costs, leaving the tone cautiously neutral.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reaffirmed 2026 distribution guidance of $0.40 per security (with $0.20 to be paid in October) but said it will not provide a quantified distribution target beyond the 1‑year period, instead reverting to its distribution policy of paying 90–110% of free cash flow (while noting 2026 is expected to be above that range due to the French temporary supplemental tax and one‑offs). Key metrics cited: operating free cash flow per security was $0.191 (down 1.5% vs H1 2025); underlying NPAT was $94.3m (up 29%); on a constant‑currency basis proportional toll revenue was up 0.6% and proportional EBITDA up 0.9% (FX weakened results, leaving proportional toll revenue and EBITDA down 3.9% and 3.6% respectively); cash received from businesses was A$296m (1% lower YoY) with A$5.8m net proceeds from the FX hedge program; pro‑forma corporate cash was A$100m; APRR priced €500m of bonds in January; a new US$150m three‑year corporate facility was established to fund the US$100m put‑option settlement (the put produced an $89.1m fair‑value movement and $37.5m settlement expense), and material non‑operating charges included $24.1m of IFM takeover costs and $16.9m of change‑of‑control employee costs.
Atlas Arteria Peers Comparison
Overall Rating
AU:BXB73Outperform
AU:TCL61.7Neutral
AU:AZJ53Neutral
AU:DBI47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | AUD 28.40B | 21.20 | 28.80% | 3.06% | 0.86% | 7.65% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 62Neutral | AUD 43.16B | 117.70 | 4.43% | 4.99% | 0.00% | 174.53% | |
| 53Neutral | AUD 6.55B | 18.61 | 8.96% | 5.91% | 5.89% | 21.43% | |
| 47Neutral | AUD 2.75B | 77.81 | 3.41% | 4.76% | 10.72% | -59.88% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:M82 | Atlas Arteria | 2.24 | -0.16 | -6.55% | |
| AU:BXB | Brambles Limited | 21.39 | -2.55 | -10.66% | |
| AU:AZJ | Aurizon Holdings Ltd. | 3.89 | 0.68 | 21.03% | |
| AU:TCL | Transurban Group Ltd. | 13.83 | 0.00 | 0.03% | |
| AU:DBI | Dalrymple Bay Infrastructure Ltd. | 5.54 | 1.30 | 30.54% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.